BioCurity Pharmaceuticals

BioCurity Pharmaceuticals

Early Stage

Because we believe that fighting cancer is hard enough!

Because we believe that fighting cancer is hard enough!


Raised this Round: Raised: $238,442

Total Commitments ($USD)



Start Date


Close Date


Min. Goal
Max. Goal
Min. Investment


Security Type

Equity - Preferred



SEC Filing Type

RegCF    Open SEC Filing

Price Per Share


Pre-Money Valuation


Year Founded



Healthcare & Pharmaceuticals

Tech Sector


Distribution Model




Capital Intensity



Jupiter, Florida

Business Type


BioCurity Pharmaceuticals, with a pre-money valuation of $36.3 million, is raising funds on StartEngine. The company is developing drugs to transform radiation therapy and prevent its side effects for cancer patients. The patented technology of BioCurity intends to reduce the side effects of radiation without affecting its effectiveness. Dr. Cheryl Baker founded BioCurity Pharmaceuticals in 2016 and completed a crowdfunding campaign on StartEngine in June 2020. The current round of crowdfunding has a minimum raise of $9,996 and a maximum raise of $599,998, and the funds will be used to meet the development milestones of the proposed drug. BioCurity Pharmaceuticals has seven issued US patents and international patents.

Summary Profit and Loss Statement

Most Recent Year Prior Year












Net Income



Summary Balance Sheet

Most Recent Year Prior Year




Accounts Receivable



Total Assets



Short-Term Debt



Long-Term Debt



Total Liabilities



Financials as of: 07/29/2020
Create a free account today to gain access to KingsCrowd analytics.

Raise History

Offering Name Close Date Platform Valuation/Cap Total Raised Security Type Status Reg Type
BioCurity Pharmaceuticals 04/29/2021 StartEngine $36,320,126 $238,442 Equity - Preferred Funded RegCF
BioCurity Pharmaceuticals 06/28/2020 StartEngine $34,019,537 $403,066 Equity - Preferred Funded RegCF
Create a free account today to gain access to KingsCrowd analytics.

Revenue History

Note: Revenue data points reflect the latest of either the most recent fiscal year's financials, or updated revenues directly from the founder, at each raise's close date.

Valuation History

Price per Share History

Note: Share prices shown in earlier rounds may not be indicative of any stock splits.

Employee History

Upgrade to gain access

Pay Monthly
Annually (Save 17%)


$25 /month
billed annually
Free portfolio tracking, data-driven ratings, AI analysis and reports
Plan Includes:
Everything in Free, plus
Company specific KingsCrowd ratings and analyst reports
Deal explorer and side-by-side comparison
Startup exit and failure tracking
Startup market filters and historical industry data
Advanced company search ( with ratings)
Get Edge Annual
Already a member? Log in here.

Ratings KingsCrowd Startup Rating Methodology Article

Blurred Ratings Bars Blurred Ratings Bars
Founders: enhance your startup's credibility on KingsCrowd. Create an account to claim this raise page.
Add to portfolio
BioCurity Pharmaceuticals on StartEngine
Platform: StartEngine
Security Type: Equity - Preferred
Valuation: $36,320,126
Price per Share: $4.25

Follow company

Follow BioCurity Pharmaceuticals on StartEngine

Buy BioCurity Pharmaceuticals's Deal Report

Warning: according to the close date for this deal, BioCurity Pharmaceuticals may no longer be accepting investments.

BioCurity Pharmaceuticals Deal Report

Get KingsCrowd’s comprehensive report on BioCurity Pharmaceuticals including:

  • How our proprietary algorithm rates their current capital raise (1-5 stars)
  • Detailed price, market, team, differentiators, performance, and risk ratings
  • Whether BioCurity Pharmaceuticals is undervalued or overvalued
  • Scores on the founding team and key personnel's background and expertise

Buy the BioCurity Pharmaceuticals deal report for only $10!

Email address:
Looking to buy more than one deal report? Get unlimited reports by upgrading to Edge